These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27878693)

  • 1. Is medicines parallel trade 'regulatory arbitrage'?
    Costa-Font J
    Int J Health Econ Manag; 2016 Dec; 16(4):321-336. PubMed ID: 27878693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel trade of pharmaceuticals: The Danish market for statins.
    Méndez SJ
    Health Econ; 2018 Feb; 27(2):333-356. PubMed ID: 28868645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parallel import of drug preparations. A study of price development of parallel import preparations versus original preparations].
    Schou HS
    Ugeskr Laeger; 1993 Jun; 155(26):2024-8. PubMed ID: 8328041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.
    Liu J; Wang L; Liu C; Zhang X
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):625-631. PubMed ID: 28503962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Competition and prices in the Mexican pharmaceutical market].
    Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
    Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
    Bergman MA; Granlund D; Rudholm N
    Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics.
    Duso T; Herr A; Suppliet M
    Health Econ; 2014 Sep; 23(9):1036-57. PubMed ID: 25139795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Price differences between generic and innovator medicines in Brazil].
    Vieira FS; Zucchi P
    Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.